"The "expert" panel (3 mediocre at best scientists)?" Are you kidding? The three experts on the panel: 1) Dr Jakob Morkenberg 2) Dr Laura Lewis 3) Dr Paulo Paixao.
Lewis & Morkenberg are on the board of WADA's
Hematological Athlete Biological Passport Working Group which is chaired by renowned anti-expert
Olaf Schumacher. The board provides expert advice, recommendations & guidance with regards to the hematological module of the ABP:
A WADA Working Group
www.wada-ama.org
Furthermore, Morkenberg & Paixao have expertise in clinical hematology & Lewis expertise with hypoxia's effect on the hematological parameters of the ABP. All three have served as anti-doping experts at many Tribunal hearings as well as testified at many CAS hearings, some involving high-profile cases from athletics.
The anti-doping experts noted sample #2 (OFF-score:
123.1) was taken at the start of the Tour de l'Avenir & sample #6 (OFF-score:
122.01) was taken one week after the national championships. These by far were the two highest OFF-scores on the profile, both meeting the 99% specificity.
All of your points & challenges were addressed by the anti-doping experts citing case studies throughout the hearing. I'm not going to go over each one here - people can read the hearing in it's entirety. I will note that under paragraph #35, the anti-doping experts unanimously concluded that none of your arguments "provided any credible explanation for the abnormalities observed on the profile."
Additionally, the Judge in the case concluded in paragraph #230 that based on the evidence presented, she was "comfortably satisfied that the rider committed an ADRV."
Btw, the ABP has been challenged numerous times over the years in CAS hearings. Paragraph #200 cites & summarizes some of those challenges - concluding that the ABP is "a reliable means of evidence for the purpose of establishing the use of a prohibited substance or method."
The ABP (hematological module) has been in use since
2009. There are over 180 ADRVs as a result of hematological anomalies. A high percentage of these cases come from athletics with Russia leading the world in ABP hematological anomalies bans with over 70! It's the only reliable method to detect blood transfusions & the off-phase of use of an ESA where the doper avoids testing positive but has hematological anomalies still present.
Remember when the test for rEPO was developed in 2000, there was a dramatic shift to blood transfusions IC (see Lance Armstrong's systematic doping regime with US Postal during the Tour). Until the ABP was developed, there was no way of detecting blood transfusions. The UCI utilized the 50% Hct upper-limit rule which only resulted in a two (2) week no-competition down time period. And this rule certainly didn't do much for the athletes that had low baseline Hct levels that could dope right up to the limit & have a significant advantage in competition.
One of Schumacher's excellent papers on the basic fundamentals of the hematological module of the ABP covering both transfusions & ESA use:
The increase of the body's capacity to transport oxygen is a prime target for doping athletes in all endurance sports. For this pupose, blood transfusions or erythropoiesis stimulating agents (ESA), such as erythropoietin, NESP, and CERA are used. As direct detection of such manipulations is...
pubmed.ncbi.nlm.nih.gov
The PDF on the Tribunal hearing: